Profile of etravirine for the treatment of HIV infection

References

• Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and AdolescentsDepartment of Health and Human Services. Federal register: November 3, 20081139
   Google Scholar
• European AIDS Clinical Society (EACS)Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. October 2008.
   Google Scholar
• GazzardBGOn behalf of the BHIVA Treatment Guidelines Writing GroupBritish HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy: 2008HIV Med2008956360818826546
   PubMed Web of Science ®Google Scholar
• HirschMSGünthardHFSchapiroJMAntiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panelClin Infec Dis20084726628518549313
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim (Canada) LtdViramune (nevirapine) Product MonographBurlington, ON7182007
   Google Scholar
• Bristol-Myers Squibb CanadaSustiva (efavirenz) Prescribing InformationMontreal, QC5272008
   Google Scholar
• WheelerWMahleKBodnarUAntiretroviral drug-resistance mutations and subtypes in drug-naive persons newly diagnosed with HIV-1 infection, US, March 2003 to October 2006 [abstract 648]14th Conference on Retroviruses and Opportunistic InfectionsLos Angeles, CAFebruary 25–282007
   Google Scholar
• AndriesKAzijnHThielemansTTMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1Antimicrob Agents Chemother2004484680468615561844
   PubMed Web of Science ®Google Scholar
• TibotecIIntelence (etravirine) Product MonographRaritan, NJ, USA82009
   Google Scholar
• DasKClarkADJLewiPJRoles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variantsJ Med Chem20044722502260
   Web of Science ®Google Scholar
• Scholler-GyureMBoffitoMPozniakALeemansRKakudaTNWoodfallBEffects of different meal compositions and fasted state on the oral bioavailability of etravirinePharmacother20082812151222
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMKakudaTNDe SmedtGVanakenHBoucheMPPeetersMA pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV–volunteersBr J Clin Pharmacol20086650851618492125
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMKakudaTNDe SmedtGWoodfallBLachaertRBeetsGPharmacokinetics of TMC125 in QD and BID regimens in HIV-1 negative volunteers [abstract A-1427]47th Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, ILSeptember 17–202007
   Google Scholar
• KakudaTNScholler-GyureMPeetersMCorbettCDe SmedtGWoodfallBPharmacokinetics of etravirine are not affected by sex, age, race, use of enfuvirtide or treatment duration in HIV-1 infected patients [abstract P34]9th International Workshop on Clinical Pharmacology of HIV TherapyNew Orleans, LAApril 7–92008
   Google Scholar
• Scholler-GyureMKakudaTNDe SmedtGWoodfallBBerckmansCPeetersMPharmacokinetics of TMC125 in HIV-1 negative volunteers with mild and moderate hepatic impairment [abstract A-1428]47th Interscience Conference on Antimicrobial Agents and ChemotherapyChicago, ILSeptember 17–202007
   Google Scholar
• AboudMCastelinoSBackDJKulasegaramREtravirine plasma levels in a patient with decompensated liver diseaseAIDS2009231293129519455013
   PubMed Web of Science ®Google Scholar
• GiguerePLa PorteCJLZhangGCameronDWPharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on hemodialysisAIDS20092374074219279448
   PubMed Web of Science ®Google Scholar
• RaoofALachau-DurandSVerbeeckJBaileyGMartensMEtravirine has no effect on fetal development in rats and rabbits [abstract TUPE0013]XVIIth International AIDS ConferenceMexico City, MexicoAugust 3–82008
   Google Scholar
• FurcoAGosraniBNicholasSWilliamsABraithwaiteWPozniakASuccessful use of darunavir, etravirine, enfuvirtide and tenofovir/emtricitabine in pregnant woman with multiclass HIV resistanceAIDS20092343443519188762
   PubMed Web of Science ®Google Scholar
• RuxrungthamKPedroRJLatiffGHConradieFDomingoPLupoSImpact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227HIV Med2008988389618795960
   PubMed Web of Science ®Google Scholar
• BoffitoMWinstonAJacksonAFletcherCVPozniakANelsonMPharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistanceAIDS2007211449145517589191
   PubMed Web of Science ®Google Scholar
• MadrugaJVCahnPGrinsztejnBHaubrichRLalezariJMillsAEfficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trialLancet2007370293817617270
   PubMed Web of Science ®Google Scholar
• LazzarinACampbellTClotetBJohnsonMKatlamaCMollAEfficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24 week results from a randomised, double-blind, placebo-controlled trialLancet2007370394817617271
   PubMed Web of Science ®Google Scholar
• KatlamaCGatellJMMolinaJMPeetersMVingerhoetsJHWoodfallBPooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients [abstract P7.13/18]11th European AIDS ConferenceMadrid, SpainOctober 24–272007
   Google Scholar
• KatlamaCHaubrichRLalezariJLazzarinAMadrugaJVSchechterMEfficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trialsAIDS2009232289230019710593
   PubMed Web of Science ®Google Scholar
• MillsACahnPMolinaJMNijsSVingerhoetsJHWitekJEtravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: pooled 96-week results [abstract MOPEB036]5th IAS Conference on HIV Pathogenesis, Treatment and PreventionCapetown, South AfricaJuly 19–222009
   Google Scholar
• CahnPMolinaJMTownerWPeetersMVingerhoetsJHBeetsG48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virologic response to etravirine [abstract TUPE0047]XVIIth International AIDS ConferenceMexico City, MexicoAugust 3–82008
   Google Scholar
• KakudaTNPeetersMCorbettCDe SmedtGSinhaRLeopoldLPharmacokinetics and pharmacodynamics of etravirine in treatment-experienced HIV-1-infected patients: pooled 48-week results of DUET-1 and DUET-2 [abstract H-4056]48th Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, DCOctober 25–282008
   Google Scholar
• HaubrichREronJThompsonMReissPWeberRPeetersMReduction in AIDS-defining events/death with etravirine compared to placebo: pooled DUET 48-week results [abstract H-1239]48th Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, DCOctober 25–282008
   Google Scholar
• EronJHaubrichRReissPThompsonMWeberRNijsSClinical endpoints reduced through etravirine use in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials [abstract MOPEB043]5th IAS Conference on HIV Pathogenesis, Treatment and PreventionCapetown, South AfricaJuly 19–222009
   Google Scholar
• YazdanpanahYFagardCDescampsDTaburetAMRoquebertBTschopeIHigh rate of virologic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug resistant virus [abstract THAB0406]17th International AIDS ConferenceMexico City, MexicoAugust 3–82008
   Google Scholar
• YazdanpanahYFagardCDescampsDTaburetAMColinCRoquebertBHigh rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trialClin Infec Dis2009491441144919814627
   PubMed Web of Science ®Google Scholar
• KerriganHTownerWKleinDFollansbeeSTreatment response among HIV patients co-enrolled in the etravirine and raltegravir expanded access programs at Kaiser Permanente [abstract H-1263]48th Annual Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, DCOctober 25–282008
   Google Scholar
• ImazAVillar del SazSRibasMACurranACaballeroEFalcoVRaltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infectionJ Acquir Immune Defic Syndr20095238238619654552
   PubMed Web of Science ®Google Scholar
• LoutfyMRiberaEFlorenceEDe WitSCastagnaARyanRSustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programmeJ Antimicrob Chemother2009 [Epub ahead of print].
   Google Scholar
• HodderSJayaweeraDMrusJRyanRWitekJGRACE (Gender, Race And Clinical Experience): etravirine subgroup analysis at week 48 [abstract H-919]49th Interscience Conference on Antimicrobial Agents and ChemotherapySan FranciscoSeptember 12–152009
   Google Scholar
• ViganoAMeroniLMarchettiGVanzulliAGiacometVFasanSSuccessful rescue therapy with a darunavir/ritonavir and etravirine antiretroviral regimen in a child with vertically acquired multidrug-resistant HIV-1Antiviral Ther200813839843
   PubMed Web of Science ®Google Scholar
• ThuretIChaixM-LTamaletCReliquetVFirtionGTriocoireJRaltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virusAIDS2009232364236619823069
   PubMed Web of Science ®Google Scholar
• CampbellTGrinsztejnBHartikainenJNijsSWitekJLong-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: pooled 96-week results from the Phase III DUET trials [abstract MOPEB038]5th IAS Conference on HIV Pathogenesis, Treatment and PreventionCapetown, South AfricaJuly 19–222009
   Google Scholar
• MillsAGrinsztejnBKatlamaCPeetersMJanssenKKakudaTNThe incidence of rash observed with the NNRTI etravirine in the Phase III DUET trials using pooled 48-week data [abstract TUPE0059]XVIIth International AIDS ConferenceMexico City, MexicoAugust 3–82008
   Google Scholar
• BenhamidaJChappeyCCoakleyEParkinNTHIV-1 genotype algorithms for prediction of etravirine susceptibility; novel mutations and weighting factors identified through correlations to phenotypeAntiviral Ther200813A142
   Web of Science ®Google Scholar
• VingerhoetsJHPeetersMAzijnHAn update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial dataAntiviral Ther200813A26
   Web of Science ®Google Scholar
• MacArthurRDHuppler HullsiekKPengGFailing therapy with efavirenz results in significantly fewer mutations limiting to etravirine than failing therapy with nevirapine: on-treatment analyses from the CPCRA FIRST StudyAntiviral Ther200813A141
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMKakudaTNStevensTAharchiFDe SmedtGPeetersMEffect of etravirine on cytochrome P450 isozymes assessed by the Cooperstown 5 + 1 cocktail [abstract A-955]48th Interscience Conference on Antimicrobial Agents and ChemotherapyWashington, DCOctober 25–282008
   Google Scholar
• SchollerMHoetelmansRMBollenSVandermeulenKPeetersMBastiaanseLNo significant interaction between TMC125 and didanosine in healthy volunteers [abstract 29]6th International Workshop on Clinical Pharmacology of HIV TherapyQuebecApril 28–302005
   Google Scholar
• KakudaTNScholler-GyureMDe SmedtGBeetsGAharchiFPeetersMAssessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteersHIV Med20091017318119207601
   PubMed Web of Science ®Google Scholar
• BoffitoMWinstonAFletcherCPozniakANelsonMMoyleGJPharmacokinetics and antiretroviral response to TMC114/r and TMC125 in combination in patients with high level viral resistance [abstract 575c]13th Conference on Retroviruses and Opportunistic InfectionsDenver, COFebruary 5–82006
   Google Scholar
• Scholler-GyureMKakudaTNAkumaSHDe ClerqIDe SmedtGSpittaelsKPharmacokinetic interaction between etravirine and lopinavir/ritonavir [abstract A1-1298]49th Interscience Conference on Antimicrobial Agents and ChemotherapySan FranciscoSeptember 12–152009
   Google Scholar
• AndersonMSKakudaTNHanleyWDMillerJLKostJStoltzRMinimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjectsAntimicrob Agents Chemother2008524228423218838586
   PubMed Web of Science ®Google Scholar
• TommasiCTempestilliMBellagambaRNotariSNicastriEPucilloLPPharmacokinetics of darunavir/ritonavir, raltegravir and etravirine coadministered in HIV-1-infected patients [abstract O_11]10th International Workshop on Clinical Pharmacology of HIV TherapyAmsterdamApril 15–172009
   Google Scholar
• BaedePPiscitelliSGrahamNVan’t KloosterGDrug interactions with TMC125, a potent next generation NNRTI [abstract A1827]42nd Interscience Conference on Antimicrobial Agents and ChemotherapySan Diego, CASeptember 27–30200227
   Google Scholar
• Scholler-GyureMWoodfallBBollenSPeetersMVandermeulenKHoetelmansRMPharmacokinetics of amprenavir and TMC125 in HIV-infected volunteers receiving TMC125 with fosamprenavir/ritonavir [abstract A-0370]46th Interscience Conference on Antimicrobial Agents and ChemotherapySan Francisco, CASeptember 27–302006
   Google Scholar
• BoffitoMJacksonALamordeMBackDJWatsonVTaylorJPharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteersJ Acquir Immune Defic Syndr20095222222719620877
   PubMed Web of Science ®Google Scholar
• Scholler-GyureMKakudaTNVan Solingen-RisteaRAharchiFDe SmedtGWitekJPharmacokinetic interaction between etravirine and fluconazole or voriconazole in HIV-negative volunteers [abstract A1-1299]49th Interscience Conference on Antimicrobial Agents and ChemotherapySan FranciscoSeptember 12–152009
   Google Scholar
• Scholler-GyureMKakudaTNWoodfallBAharchiFPeetersMVandermeulenKEffect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindroneContraception200980445219501215
   PubMed Web of Science ®Google Scholar
• Van HoutteMPicchioGVan Der BorghtKA comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotypeJ Med Virol2009811702170919697398
   PubMed Web of Science ®Google Scholar